mTOR is central in this switch, regulating both catabolism and anabolism, and mTOR inhibitors are commonly used in cancer treatment, such as rapamycin and its analogs, collectively known as rapalogs, and ATP-competitive mTOR kinase inhibitors, which are designed to target ATP binding sites in the catalytic domains of mTOR. This evidence concerns the gene MTOR and cancer.